Back to search

Ireland· IE-PA-EU/1/18/1340/007-009

TAKHZYRO 150 mg solution for injection in pre-filled syringe

A lanadelumab product containing lanadelumab, registered in Ireland by Takeda Pharmaceuticals International AG Ireland Branch. The same ATC class is registered in 15 of our 19 countries.

ATC B06AC05

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedTAKHZYRO 150 mg solution for injectio…ATCB06AC05REGISTER NO.IE-PA-EU/1/18/1340/00…PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Lanadelumab is registered in 15 of 19 countries.

Countries holding a registration under ATC B06AC05 (lanadelumab), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 10 of them publish a price we can compare per daily dose

Lanadelumab · ATC B06AC05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lanadelumab costs, country by country.

Normalised to the WHO defined daily dose (21.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Lanadelumab · price per daily dose (21.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$857.11
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
LANADELUMAB
Manufacturer
Takeda Pharmaceuticals International AG Ireland Branch
Country
Ireland (IE)
ATC code
B06AC05
ATC class
Lanadelumab
Defined daily dose
21.4 mg, P
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/18/1340/007-009

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/7c7bd439-734e-4d18-bd9d-c6a13e31504c
GET /v1/drugs/7c7bd439-734e-4d18-bd9d-c6a13e31504c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "routes": [
    "Subcutaneous use"
  ],
  "source": "hpra",
  "atc_all": [
    "B06AC05"
  ],
  "strength": null,
  "pa_number": "EU/1/18/1340/007-009",
  "substances": [
    "LANADELUMAB"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "15/11/2023",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about lanadelumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.